• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Skystar Bio-Pharmaceutical Developing Avian Influenza (H5N1) Vaccine for Humans and Animals

Posted on: Tuesday, 14 February 2006, 12:00 CST

Skystar Bio-Pharmaceutical (OTC BB: CGPN), a leading Bio-Pharmaceutical Company in China, announced that they are developing the highly efficient Avian Influenza Inactivated Vaccine for poultry, birds and humans.

The challenge in making an effective Avian Influenza Vaccine is to solve the issues around the mutation of the actual virus. Once an antigen (vaccine) is introduced to the virus, the virus will mutate rendering the antigen ineffective. For example, a bird or chicken may not show any signs of clinical symptoms after inoculation, but the virus can still hide in its lungs or beak. While hiding, the virus will mutate and become immune to the vaccine. This bird or chicken would now put the rest of the poultry products at risk because it is a "carrier" of a stronger mutated virus.

Skystar is in the process of developing an inactived vaccine. As an inactived vaccine, the Avian Influenza Vaccine merely contains antigen contents but none of the active viral residue, formulated to the latest viral strain. This helps build up immunity in animals and people. This is the same premise in which the annual flu vaccine is based upon.

Current virus technology uses a chicken embryo to breed the virus and produce the vaccine. This technology struggles to keep up with the ever-changing viral strains and is not able to produce enough vaccine to keep up with the demand. Skystar is designing a new technology that is based on a multi-surface cell propagating system. The result is that this process is more controllable and can easily keep up with the virus mutations. Further, this process is more efficient and as a result can be massed produced to keep up with high demand.

Skystar expects to complete their revolutionary vaccine as early as 1st quarter 2007.

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company, Ltd. (OTC BB: CGPN). Established in 1997, Skystar is a fully GMP certified bio-pharmaceutical company that produces and distributes vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 60 state-of-the-art products and has over 50 more in the development stage. One of the prominent products in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed existing, strategic sales distribution in 27 provinces and regions in China. The State Ministry of Agriculture in China has authorized the additional construction of a new bio-pharmaceutical facility, which will also conform to GMP standards. For more information about Skystar Bio-Pharmaceutical Company, Ltd.'s innovative products and growth plan, please visit www.xa-tx.com or contact Scott Cramer scramer@cybergroupnetwork.com or (407) 645-4433.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Skystar's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

 Contact: Skystar Bio-Pharmaceutical Company, Ltd. Scott Cramer Contact via http://www.marketwire.com/mw/emailprcntct?id=FF6AAB394CD0EE3E (407) 645-4433  

SOURCE: The Cyber Group Network Corporation

Source: MARKET WIRE

More News in this Category